Delcath Announces Ratio for Reverse Split Authorization

5/1/18

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s Board of Directors has authorized a reverse stock split of the Company’s common stock at a ratio of 1-for-500 (the Reverse Stock Split Authorization). The Company’s Board of Directors was authorized to effect the reverse split by shareholder approval of its Consent Solicitation filed with the Securities Exchange Commission (SEC) on February, 26, 2018. The proposal to effect a reverse split was approved by shareholders on April 6, 2018 by a vote of 52.8%. The reverse split will be effected prior to the initiation of trading on May 2, 2018.

Beginning with the May 2, 2018 trading date, Delcath’s shares will be designated by the symbol DCTHD for 20 trading days, and thereafter will revert to the symbol DCTH.

About Delcath Systems

Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.